Gotratix A-18 Muscle Peptide Bioregulator

Produkt Beschreibung

1. Classification and Chemical Overview

Gotratix A-18 Muscle Peptide Bioregulator is an organ-specific biological response modifier categorised within the cytomax family of natural peptide bioregulators. Chemically, the active substance comprises a purified, low-molecular-weight polypeptide fraction isolated from the striated skeletal muscle tissue of young mammalian livestock, predominantly bovine donors (Bos taurus). The extraction protocol utilises gentle acetic acid digestion coupled with sequential ultrafiltration to isolate polypeptide fractions with an upper molecular mass cut-off strictly restricted below $5\text{ to }10\text{ kDa}$. The biologically active fraction comprises ultra-short oligopeptides spanning 2 to 6 amino acid residues, trace endogenous nucleopeptides, and tissue-specific regulatory motifs. Synthetic counterparts (cytogens) reproduce targeted functional sequences chemically—most commonly short di-, tri-, or tetrapeptide motifs—using solid-phase peptide synthesis. The formulation is presented in hard gelatin or hydroxypropyl methylcellulose (HPMC) capsules containing standard pharmaceutical excipients, such as microcrystalline cellulose, lactose, and calcium stearate.

Within the United Kingdom regulatory framework, Gotratix A-18 possesses no marketing authorisation (MA) from the Medicines and Healthcare products Regulatory Agency (MHRA). It is not catalogued in the British National Formulary (BNF) and is not scheduled as a Prescription Only Medicine (POM), Pharmacy (P) medicine, or General Sales List (GSL) drug under the Human Medicines Regulations 2012. Within the UK, this preparation is commercialised strictly as a non-medicinal food supplement or chemical research material governed by the Food Safety Act 1990 and the Nutrition and Health Claims (England) Regulations. In accordance with domestic trading standards and statutory food supplement legislation, commercial distributors are legally prohibited from articulating therapeutic or medicinal claims concerning the prevention, diagnosis, mitigation, or treatment of clinically established neuromuscular or musculoskeletal pathologies (such as muscular dystrophies, myasthenia gravis, amyotrophic lateral sclerosis, rhabdomyolysis, sarcopenia, or inflammatory myopathies).

2. Mechanism of Action and Pharmacodynamics

The pharmacodynamic profile of Gotratix A-18 is rooted in the tissue-specific epigenetic model of short-chain peptide bioregulation, operating primarily via nuclear transactivation and cellular homeostasis within skeletal myocytes and muscle satellite cells:

• Epigenetic and Transcriptional Regulation: Owing to low molecular mass, compact hydrodynamic volume, and neutral-to-amphiphilic surface charges, the ultra-short oligopeptides in Gotratix A-18 cross the sarcolemma of multinucleated myofibres and muscle satellite cells. They translocate across the nuclear pore complex into the nucleoplasm, where they bind site-specifically to complementary nucleotide sequences within the major and minor grooves of double-stranded genomic DNA and nucleosomal core histones. This interaction alters nucleosomal packaging, facilitates chromatin unwinding from heterochromatin to open euchromatin, and recruits RNA polymerase II, modulating the transcription of structural and functional genes essential for myofibrillar integrity and functional adaptation.

• Myofibrillar Protein Synthesis and Satellite Cell Differentiation: In vitro and preclinical models indicate that skeletal muscle peptides stimulate the transcriptional synthesis of contractile and structural proteins, including sarcomeric actin, myosin heavy chain (MHC) isoforms, and troponin complexes. Furthermore, they support the expression of myogenic regulatory factors (MRFs)—specifically MyoD, myogenin, and MRF4—promoting the proliferation and directed differentiation of quiescent satellite cells into functional myoblasts to support structural micro-repair following mechanical microtrauma.

• Mitochondrial Homeostasis and Metabolic Efficiency: Skeletal muscle peptide bioregulators promote the functional maintenance of metabolic enzymes involved in aerobic respiration and ATP resynthesis, supporting mitochondrial inner membrane potential and the baseline activity of citrate synthase and succinate dehydrogenase. This optimization of cellular energetic turnover facilitates physiological resistance to metabolic fatigue during prolonged muscular contraction without altering baseline central motor drive.

• Cytoprotection and Apoptosis Attenuation: Exposure to skeletal muscle peptide fractions reduces cellular apoptosis induced by oxidative stress, prolonged mechanical load, or ischaemia-reperfusion injury. This cytoprotective action is mediated by downregulating pro-apoptotic markers (caspase-3 and Bax), preserving mitochondrial inner membrane integrity ($\Delta\Psi_m$), and transcriptionally upregulating endogenous enzymatic antioxidants, notably superoxide dismutase (SOD) and glutathione peroxidase within striated muscle fibers.

3. Approved UK Clinical Indications and Therapeutic Scope

Gotratix A-18 possesses no approved clinical indications in the United Kingdom. No randomized, double-blind, multicentre clinical trials meeting the statutory criteria of the MHRA have been conducted to establish clinical efficacy, therapeutic reproducibility, or toxicological safety profiles.

The National Institute for Health and Care Excellence (NICE) does not endorse, recommend, or integrate Gotratix A-18 into any formal clinical pathway. It is entirely absent from clinical guidelines governing motor neurone disease (NG42), falls in older people: assessing risk and prevention (CG161), or general rehabilitation after critical illness (CG83).

The application of Gotratix A-18 is confined strictly to non-clinical consumer wellness contexts and preliminary laboratory research. In exploratory literature and private functional health sectors, it is investigated for:

• Supporting functional physiological resilience of the musculoskeletal system during non-pathological, age-related skeletal muscle loss (early age-related physical frailty).

• Complementary nutritional support during convalescence following intense athletic conditioning, high-volume resistance exercise, or heavy physical exertion.

• Maintenance of baseline myofibrillar protein synthesis and motor endurance in populations undergoing physical reconditioning.

• Preclinical animal models examining muscle architecture stabilization, cross-sectional fibre area preservation, and metabolic recovery under conditions of prolonged skeletal muscle unweighting or hypokinesia.

Gotratix A-18 holds no status within the NHS drug tariff, cannot be prescribed on NHS prescription forms (FP10), and must never replace validated clinical treatments, including targeted physiotherapy, clinical nutritional support, oral or parenteral rehydration, licensed disease-modifying therapies for neuromuscular disorders, or clinical management of acute rhabdomyolysis.

4. Pharmacokinetic Profile and Metabolic Fate

Because Gotratix A-18 is formulated as an oral capsule, its pharmacokinetic disposition is determined by gastrointestinal transport and physiological peptide clearance kinetics:

• Absorption: Crude protein macromolecules undergo extensive cleavage in the stomach by pepsin and in the small intestine by pancreatic endopeptidases (trypsin, chymotrypsin). However, the ultra-short di-, tri-, and tetrapeptides present in Gotratix A-18 exhibit structural resistance to complete brush-border aminopeptidase degradation. These intact short peptide sequences cross the apical enterocyte membrane into the portal circulation via the low-affinity, high-capacity proton-coupled peptide transporter 1 (PEPT1). Peak plasma concentrations ($T_{max}$) of intact circulating oligopeptides typically occur within 20 to 50 minutes following oral ingestion.

• Distribution: Following mesenteric absorption and portal transit, the peptides enter the systemic vascular compartment. With a low molecular weight and hydrophilic properties, the apparent volume of distribution ($V_d$) corresponds closely to total extracellular fluid volume. Preclinical biodistribution assays demonstrate selective tropism toward striated muscular tissues, crossing skeletal muscle capillary networks to access the interstitial space, sarcolemma, and satellite cell niches. Plasma protein binding is negligible ($<5\%$).

• Biotransformation: Gotratix A-18 does not undergo hepatic clearance via the cytochrome P450 (CYP450) microsomal monooxygenase system (e.g., CYP1A2, CYP2D6, CYP3A4). Systemic clearance is mediated entirely by circulating plasma aminopeptidases, carboxypeptidases, and cellular endopeptidases, which rapidly hydrolyse peptide bonds into native constituent individual L-amino acids (such as L-alanine, L-glutamic acid, and L-aspartic acid). These amino acids enter endogenous amino acid turnover and protein synthesis pools.

• Elimination: Systemic elimination of intact peptides is rapid, with an effective half-life ($t_{1/2}$) ranging between 15 and 60 minutes. Direct renal excretion of intact macromolecular peptides is negligible; end-stage metabolites are cleared as urinary urea, with trace carbon atoms exhaled as carbon dioxide via respiratory gas exchange.

5. Physiological Effects and Adverse Event Spectrum

The primary physiological effect documented in preclinical investigations is the stabilization of contractile apparatus function, characterized by maintained isometric muscle twitch force, preservation of muscle fibre diameter during periods of disuse, and reduced systemic release of biochemical markers of mechanical muscle damage (such as creatine kinase and lactate dehydrogenase) following intense contractile activity. In animal models of experimental immobilization, these agents demonstrate structural maintenance of myofibrillar alignment, reduced interstitial fibrosis, and faster recovery of dynamic motor performance without inducing abnormal cardiac or skeletal muscle hypertrophy.

Because Gotratix A-18 has not undergone structured, large-scale Phase I–IV clinical pharmacovigilance surveillance, documentation of adverse drug reactions is derived primarily from observational cohorts and preclinical animal toxicology:

• Very Common ($\ge 1/10$): None documented in clinical literature.

• Common ($1/100$ to $<1/10$): Mild, self-limiting gastrointestinal symptoms following oral intake, including transient nausea, epigastric fullness, mild dyspepsia, and abdominal bloating.

• Uncommon ($1/1,000$ to $<1/100$): Transient sensations of mild cephalalgia; mild, localized cutaneous pruritus or macular rash; transient subjective sensations of localized muscle tension or stiffness.

• Rare ($1/10,000$ to $<1/1,000$): Type I immediate allergic hypersensitivity reactions (urticaria, angioedema, or bronchospasm), principally triggered in atopic individuals sensitized to bovine structural protein residues.

• Biological and Diagnostic Hazards: Unregulated preparations derived from non-certified mammalian sources carry theoretical risks of transmissible spongiform encephalopathies (TSE/BSE) if origin verification is absent. Crucially, self-administering unlicensed bioregulators to manage progressive muscular weakness, muscle wasting, dark reddish-brown urine, or severe exertional cramps presents a critical clinical hazard by potentially delaying diagnostic evaluation for acute rhabdomyolysis, myasthenia gravis, metabolic myopathies, or progressive neurological disease.

6. Contraindications, Drug Interactions, and Clinical Precautions

The handling and administration of Gotratix A-18 require strict adherence to fundamental neuromuscular, renal, and pharmacological safety parameters:

• Contraindications:

  • Documented hypersensitivity or history of allergic anaphylaxis to bovine-derived biological substances, gelatin, or any formulation excipients.

  • Acute rhabdomyolysis: Absolute contraindication in active rhabdomyolysis or severe myoglobinuria; acute release of muscle breakdown products into circulation demands emergency medical stabilisation, intravenous fluid resuscitation, and renal protection.

  • Active neuromuscular or myogenic neoplasms: Absolute contraindication in patients with known or suspected rhabdomyosarcoma, leiomyosarcoma, or metastatic soft-tissue sarcomas. Modulating transcriptional activity, cellular viability, or trophic signalling in neoplastic tissue is clinically hazardous.

  • Severe acute renal impairment: Contraindicated in acute kidney injury (AKI) or severe chronic kidney disease (CKD Stages 4–5), where nitrogenous peptide degradation metabolites must be clinically monitored.

  • Pregnancy and lactation: Absolute contraindication due to an absence of embryotoxicity, teratogenicity, and developmental reproductive safety data, alongside unknown secretion into human breast milk.

  • Paediatric population: Contraindicated in infants, children, and adolescents under 18 years due to an absence of safety and developmental data in the growing paediatric neuromuscular system.

• Drug Interactions:

  • Neuromuscular blocking agents and muscle relaxants (e.g., baclofen, dantrolene, botulinum toxin): No formal pharmacokinetic studies exist, but theoretical alterations in intracellular calcium handling or myofibrillar sensitivity warrant clinical observation.

  • Statin therapy (HMG-CoA reductase inhibitors): Patients experiencing statin-associated muscle symptoms (SAMS) or statin-induced myopathy must not discontinue prescribed statins or avoid clinical creatine kinase assessment in favor of unlicensed peptide bioregulators.

  • Cytochrome P450 interactions: There are no documented pharmacokinetic induction or inhibition interactions with hepatic CYP450 isoenzymes.

• Clinical Precautions:

  • Neuromuscular Alarm Symptoms (“Red Flags”): Patients presenting with red flag symptoms—such as progressive symmetrical or asymmetrical muscle weakness, ptosis, diplopia, difficulty swallowing or speaking (dysphagia/dysarthria), dark “tea-coloured” urine following exercise, severe acute localized muscle swelling, or unexplained fasciculations—mandate immediate emergency medical admission or urgent specialist neurology referral rather than self-care.

  • Creatine Kinase (CK) and Neurological Evaluation: Individuals experiencing uncharacteristic or worsening muscle weakness require formal medical evaluation, including serum creatine kinase, electrolytes, erythrocyte sedimentation rate (ESR), electromyography (EMG), and nerve conduction studies, prior to introducing any supplementary product.

  • Source Purity: Clinicians and researchers must verify that natural mammalian extracts possess documented batch-specific certification confirming extraction from BSE-free herds and compliance with UK/EU biological safety criteria.

Weitere Informationen